Abstract：Objective To investigate the application of cardiac stenting and thrombolysis and reperfusion in patients with ST-segment elevation acute myocardial infarction (STEMI).Methods Forty-six patients with STEMI admitted to our hospital from December 2016 to October 2018 were enrolled in the study.They were divided into control group (n=23) and observed group (n=23) according to the random number table method.The patients in the control group were treated with cardiac stenting.The patients in the observation group were treated with thrombolysis and reperfusion.The serum myocardial necrosis markers, inflammatory factors and left ventricular ejection fraction (LVEF) and left ventricular end-diastolic diameter (LVEDD) and primary endpoint (mortality, rate of re-infarction) were observed in the two groups.Results Creatine kinase isoenzyme(CK-MB),cardiac troponin I(cTnI), serum high-sensitivity C-reactive protein(hs-CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-10 (IL-10) were lower than those of the control group, the differences were statistically significant (P<0.05).The LVEF of the observation group was higher than that of the control group and LVEDD was lower than the control group, the difference was statistically significant(P<0.05).The mortality and re-infarction rate of the observation group were lower than those of the control group, and the differences were statistically significant (P<0.05).Conclusion The effect of thrombolysis and reperfusion treating STEMI is more significant,and it can effectively improve the relevant indicators of patients.It is more advantageous than cardiac stenting and is suitable for clinical development and implementation.
Huded CP，Johnson M，Kravitz K，et al.Four-step protocol for disparities in STEMI care and outcomes in women[J].J Am Coll Cardiol，2018，71（19）：S0735109718333709.
Rhyou HI，Park TH，Cho YR，et al.Clinical factors associated with the development of atrial fibrillation in the year following STEMI treated by primary PCI[J].J Cardiol，2018，71（2）：S0914508717302368.
京公网安备 11010502046607号